SSH aims to raise $4.3m for Bio-Layer
Friday, 16 September, 2005
Sydney-based SSH Medical (ASX:SSH) has started accepting applications for subscriptions to raise approximately $4.3 million to provide working capital for material science company Bio-Layer, which SSH is acquiring.
Bio-Layer is developing biological surface-coating technology, with an initial focus on immunoassays and diagnostic tests.
SSH is currently receiving negligible commercial returns from its VedaScope business and will divest its MediStation operations as part of the overall transaction.
SSH will issue 15.2 million shares at AUD$0.28 and 7.6 million listed, tradable options will also be issued, free of charge, on a one for two basis. The prospectus was released on September 8.
The offer is being sponsored by EG Capital and is being made to SSH's existing 2,300 shareholders, clients of EG Capital and selected brokers. Prior to the capital raising, SSH anticipates undertaking a 10 for 1 share consolidation.
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
